PD-1 和 PD-L1 抑制剂市场：按产品、分销管道 - 2023-2030 年全球预测

预计到 2023 年，全球 PD-1 和 PD-L1 抑制剂市场将大幅成长，达到 371.1 亿美元，年复合成长率为 20.52%，预计到 2030 年将达到惊人的 1,376.5 亿美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球PD-1和PD-L1抑制剂市场至关重要。透过检查业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发地区、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.PD-1和PD-L1抑制剂的全球市场规模和预测是多少？

2.在预测期内，COVID-19对全球PD-1和PD-L1抑制剂市场的阻碍因素和影响为何？

3.预测期间全球PD-1和PD-L1抑制剂市场有哪些产品/细分市场/应用/领域值得投资？

4.PD-1和PD-L1抑制剂全球市场的竞争策略是什么？

5.PD-1和PD-L1抑制剂全球市场的技术趋势和法律规范是什么？

6.全球PD-1和PD-L1抑制剂市场主要厂商的市占率是多少？

7. 哪些型态和策略性措施被认为适合进入PD-1和PD-L1抑制剂的全球市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

• 市场动态
  • 促进因素
    • 老年人口增加导致癌症罹患率增加
    • 增加患者支持计划的存在
    • 公众意识不断提高，医疗费用不断上涨
  • 抑制因素
    • 昂贵的癌症免疫疗法
  • 机会
    • pd1 和 pdl1 抑制剂的研究活动增加
    • 癌症筛检的技术创新和进步
  • 任务
    • 严格法规场景
• 市场趋势
• COVID-19 的累积影响
• 俄罗斯-乌克兰衝突的累积影响
• 高通膨的累积效应
• 波特五力分析
• 价值炼和关键路径分析
• 法律规范
• 客户客製化

第6章PD-1 和 PD-L1 抑制剂市场：依产品

• 阿替利珠单抗
• 阿维鲁单抗
• 度瓦鲁单抗
• 纳武单抗
• 帕博利珠单抗

第7章PD-1 与 PD-L1 抑制剂市场：依通路

• 医院药房
• 网路药房
• 零售药房

第8章美洲PD-1和PD-L1抑制剂市场

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第9章亚太PD-1和PD-L1抑制剂市场

• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第10章欧洲、中东和非洲PD-1和PD-L1抑制剂市场

• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第11章竞争形势

• FPNV定位矩阵
• 市占率分析：主要企业
• 竞争情境分析：主要企业

第12章上市公司名单

第13章附录

• 讨论指南
• 关于许可证和定价

The Global PD-1 & PD-L1 Inhibitors Market is forecasted to grow significantly, with a projected USD 37.11 billion in 2023 at a CAGR of 20.52% and expected to reach a staggering USD 137.65 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global PD-1 & PD-L1 Inhibitors Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global PD-1 & PD-L1 Inhibitors Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Product, market is studied across Atezolizumab, Avelumab, Durvalumab, Nivolumab, and Pembrolizumab. The Nivolumab is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. The Online Pharmacies is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global PD-1 & PD-L1 Inhibitors Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global PD-1 & PD-L1 Inhibitors Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global PD-1 & PD-L1 Inhibitors Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global PD-1 & PD-L1 Inhibitors Market?

4. What is the competitive strategic window for opportunities in the Global PD-1 & PD-L1 Inhibitors Market?

5. What are the technology trends and regulatory frameworks in the Global PD-1 & PD-L1 Inhibitors Market?

6. What is the market share of the leading vendors in the Global PD-1 & PD-L1 Inhibitors Market?

7. What modes and strategic moves are considered suitable for entering the Global PD-1 & PD-L1 Inhibitors Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. PD-1 & PD-L1 Inhibitors Market, by Product, 2022 vs 2030
• 4.3. PD-1 & PD-L1 Inhibitors Market, by Distribution Channel, 2022 vs 2030
• 4.4. PD-1 & PD-L1 Inhibitors Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of cancer coupled with growing geriatric population
    • 5.1.1.2. Growing presence of patient assistance programs
    • 5.1.1.3. Rising public awareness and increasing healthcare expenses
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of cancer immunotherapy
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing research activities in pd1 and pdl1 inhibitors
    • 5.1.3.2. Technological innovations and advancements in cancer screening procedures
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory scenario
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. PD-1 & PD-L1 Inhibitors Market, by Product

• 6.1. Introduction
• 6.2. Atezolizumab
• 6.3. Avelumab
• 6.4. Durvalumab
• 6.5. Nivolumab
• 6.6. Pembrolizumab

7. PD-1 & PD-L1 Inhibitors Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Hospital Pharmacies
• 7.3. Online Pharmacies
• 7.4. Retail Pharmacies

8. Americas PD-1 & PD-L1 Inhibitors Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific PD-1 & PD-L1 Inhibitors Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa PD-1 & PD-L1 Inhibitors Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. PD-1 & PD-L1 INHIBITORS MARKET RESEARCH PROCESS
• FIGURE 2. PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2022 VS 2030
• FIGURE 3. PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
• FIGURE 5. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
• FIGURE 6. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. PD-1 & PD-L1 INHIBITORS MARKET DYNAMICS
• FIGURE 8. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. PD-1 & PD-L1 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. PD-1 & PD-L1 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. PD-1 & PD-L1 INHIBITORS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 5. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 11. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 19. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 21. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 22. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 24. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 32. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 34. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 36. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. INDONESIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. INDONESIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 40. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. MALAYSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. MALAYSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. PHILIPPINES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. PHILIPPINES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. SINGAPORE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 46. SINGAPORE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. TAIWAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. TAIWAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. THAILAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. THAILAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. VIETNAM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. VIETNAM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. DENMARK PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 59. DENMARK PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. EGYPT PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 61. EGYPT PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. FINLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 63. FINLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 65. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. ISRAEL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. ISRAEL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. NETHERLANDS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 73. NETHERLANDS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 74. NIGERIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. NIGERIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. NORWAY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 77. NORWAY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. POLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. POLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. QATAR PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 81. QATAR PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 85. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. SWEDEN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. SWEDEN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. SWITZERLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 93. SWITZERLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. TURKEY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. TURKEY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 97. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. PD-1 & PD-L1 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 101. PD-1 & PD-L1 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 102. PD-1 & PD-L1 INHIBITORS MARKET LICENSE & PRICING